Cipla Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Cipla Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news and updates on Cipla Ltd. from all sources in a single place.

Load latest

Cipla Ltd.

06 Jan 2025

1553.40

-1.55%

Board Meeting

CIPLA LTD. - 500087 - Board Meeting Intimation for Meeting Of The Board Of Directors Of …

BSE India

CIPLA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 31st December, 2024.

pdf

Cipla Ltd.

06 Jan 2025

1553.40

-1.55%

Cipla launches CipAir mobile app for first-line asthma screening in India

Business Standard

The app aims to assess users' likelihood for asthma, thereby enabling timely intervention and management

Sharekhan increased Buy price target of Cipla Ltd. to 1754.0 on 02 Sep, 2025.

Cipla Ltd.

20 Dec 2024

1553.40

-1.55%

GST authority imposes Rs 1 cr fine on Cipla for inadmissible credit claim

Business Standard

Pharma major Cipla Ltd on Friday said a fine of over Rs 1 crore has been imposed on the company by GST authority for alleged inadmissible credit claim. The company has received an order dated December 18, 2024 passed by the GST authority, imposing a penalty of Rs 1,11,94,324 under applicable provisions of the Central Goods and Services Tax Act, 2017, Cipla said in a regulatory filing. "The order has been passed by GST Authority on the contention that the company has availed inadmissible TRAN-1 credit. The GST Authority has ordered for recovery of the same along with applicable interest and penalty," it added. Cipa said based on assessment of facts and prevailing law, it is "of the view that the penalty levied is arbitrary and unjustified". "The company will file necessary appeals with the appellate authority in this regard. There is no material impact on the company's financials or operations due to the said order," it added.

Sharekhan increased Buy price target of Cipla Ltd. to 1754.0 on 02 Sep, 2025.

Cipla Ltd.

20 Dec 2024

1553.40

-1.55%

Company Update

CIPLA LTD. - 500087 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) …

BSE India

Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

pdf

Cipla Ltd.

17 Dec 2024

1553.40

-1.55%

Cipla shares rise over 2% as Kotak forecasts better days ahead, upgrades rating to buy'

Economic Times

Cipla shares rose by 2.4% to Rs 1,483.40 on Tuesday after Kotak Institutional Equities upgraded the stock from "add" to "buy," with a target price of Rs 1,725. This suggests a potential upside of over 16% from the current levels.

Cipla Ltd. has an average target of 1717.33 from 9 brokers.

Cipla shares gain; Kotak upgrades stock to 'Buy' from 'Add'; check target

Business Standard | 17 Dec 2024

Cipla Ltd.

12 Dec 2024

1553.40

-1.55%

Cipla's inhaled insulin' from US' MannKind Corp adds a layer of convenience' for those with diabetes

Business Line

Recently, India's Central Drugs Standard Control Organisation gave Cipla the approval to exclusively distribute and market Afrezza (human insulin) inhalation powder in India

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

HSBC bullish on Indian pharma stocks for 2025

Economic Times | 12 Dec 2024 1 more

Cipla Ltd.

11 Dec 2024

1553.40

-1.55%

Cipla to bring in inhaled insulin Afreeza from US' MannKind Corporation

Business Line

The Central Drugs Standard Control Organisation (CDSCO) has given Cipla the approval to exclusively distribute and market Afrezza (human insulin) inhalation powder, in India

Cipla Ltd. has an average target of 1717.33 from 9 brokers.

Cipla gets approval to market Afrezza insulin inhalation powder in India

Business Standard | 11 Dec 2024

Cipla Ltd.

05 Dec 2024, 09:15PM

1553.40

-1.55%

Company Update

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 5th December, 2024 has allotted 1,532 fully paid-up equity shares of INR 2 each, pursuant to exercise of employee stock options/stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company

pdf